^
Association details:
| Biomarker: | PTEN expression |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
Excerpt:
In patients with absent or decreased tumor PTEN expression, the decreased risk of disease progression with T-DM1 relative to that with CL (HR, 0.55; 95% CI, 0.39–0.78) was greater than in patients with normal-to-increased tumor PTEN expression (HR, 0.78; 95% CI, 0.32–1.91) (Table 1). This relationship was not observed for OS (decreased PTEN expression: HR, 0.52; 95% CI, 0.32–0.86; normal-to-increased PTEN expression: HR, 0.43; 95% CI, 0.14–1.32; Table 2).
DOI:
10.1158/1078-0432.CCR-15-2499
Trial ID:
